MediWound Ltd.

Stage 4 · Declining · week 39

As of Oct 22, 2026, MediWound is in Stage 4, the downtrend phase, now in week 39 (since Jan 20, 2026). It closed at $12.18, 37.1% below its 52-week high and below its 200-day average, which is falling.

$12.18

+0.66% today

$157M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MDWD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S2 24w

S4 39w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 4w → S2 24w → S3 2w → S2 10w → S3 12w → S2 3w → S1 2w → S2 8w → S3 1w → S4 5w → S1 1w → S2 11w → S3 5w → S4 6w → S1 10w → S4 39w current

Total tracked: 164 weeks across 17 stage runs.

MDWD among Biotechnology298th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…298	MDWDMediWound Ltd.	Stage 4 · wk 39	31	−10.8%

vs 52W High

-37.1%

$11.85 lo$19.37 hi

37.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 39

1w13w26w

Week 39, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-20.9%

200 DMA: $15.39 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.91x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.8%

-14.4%

-26.8%

YTD

-33.9%

-34.7%

Scan Membership

Breakout Watch

Latest: 2025-05-27

8 appearances in last 60 days. First seen: 2020-07-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 39 · Vol 0.91x

2026-10-21S4

Wk 39 · Vol 1.54x

2026-10-20S4

Wk 38 · Vol 2.52x

2026-10-19S4

Wk 38 · Vol 2.12x

2026-10-16S4

Wk 38 · Vol 0.37x

2026-10-15S4

Wk 38 · Vol 1.04x

2026-10-14S4

Wk 38 · Vol 1.03x

2026-10-13S4

Wk 37 · Vol 0.91x

2026-10-12S4

Wk 37 · Vol 0.74x

2026-10-09S4

Wk 37 · Vol 1.05x

2026-10-08S4

Wk 37 · Vol 1.19x

2026-10-07S4

Wk 37 · Vol 0.83x

Moving averages & range

50 DMA

$13.13

200 DMA

$15.39

52W High

$19.37

52W Low

$11.85

5D Low

$11.85

Resistance levels (recent highs)

20d High

$13.93

60d High

$14.39

120d High

$17.44

250d High

$19.37

Next resistance

+14.4%

to 20d High

ROE

-72.4%

Profit margin -170.1%

Dividend Yield

0.00%

P/B 4.4

MediWound: quick answers

What stage is MediWound in?

As of Oct 22, 2026, MediWound (MDWD) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 20, 2026 and is in week 39. What the four stages mean

Is MediWound in an uptrend?

No. MediWound is in a Stage 4 downtrend. It trades 20.9% below its 200-day average, which is falling.

How far is MediWound from its 52-week high?

MediWound closed at $12.18 on Oct 22, 2026, 37.1% below its 52-week high of $19.37. Its 52-week low is $11.85.

How has MediWound performed over the past year?

As of Oct 22, 2026, MediWound is down 34.7% over the past year and down 33.9% so far in 2026.

Which sector and industry is MediWound in?

MediWound is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.